BURLINGTON, Mass., April 24, 2012 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of lasers and light systems for aesthetic treatments, is pleased to announce the launch of the Emerge™ Fractional Laser – an easy-to-use, affordable fractional non-ablative laser designed to help new and growing aesthetic practices easily offer laser skin rejuvenation procedures.
"The Emerge Fractional Laser represents Palomar's commitment towards making the benefits of our leading fractional technology available to a wide audience," remarked Joseph P. Caruso, President and Chief Executive Officer. "We have capitalized on our advances in microfractional laser technology to develop the Emerge laser, at the right price point and with specifications and features that are ideal for new and growing aesthetic practices interested in offering high-quality fractional non-ablative treatments to the growing population of consumers seeking to improve the appearance of their skin."
"This is a great procedure for those patients who want less downtime and are willing to come more frequently for treatments. All of my patients noticed smoother skin and were pleased with the results," said Arielle Kauvar, MD, founding director of New York Laser & Skin Care.
The Emerge laser is a non-ablative fractional laser cleared by the United States Food and Drug Administration for skin resurfacing procedures and the treatment of facial wrinkles and fine lines, as well as pigmented lesions. Featuring an intuitive user interface and pre-set treatment parameter options, the Emerge laser is a compact, professional laser device designed to help practices expand, build, and complement their aesthetic service offerings.
To learn more about the Emerge Fractional Laser, please visit www.palomarmedical.com/emerge.
About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of laser- and light-based systems for aesthetic treatments.
Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription.
As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, fractional laser device for the treatment of periorbital wrinkles. Palomar introduced the PaloVia™ Skin Renewing Laser™ in December 2010. In December 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment.
There are now millions of laser- and light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas, salons, and homes. Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.
For more information on Palomar and its products, visit Palomar's website at palomarmedical.com.
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2011 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.